Michela Luciano, PhD,  Science Writer—

Researchers in Italy have developed a new experimental compound called 3b, which has shown early promise as a dual-action therapy for cystic fibrosis (CF). It addresses the dysfunction of the CFTR protein that causes the disease, as well as protects against viral threats that can worsen lung problems. In…

Vertex Pharmaceuticals presented new data highlighting additional clinical benefits and improved outcomes in people with cystic fibrosis (CF) treated with the triple combination Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) or other CFTR modulators. The data also suggest that Alyftrek may lead to fewer pulmonary exacerbations (flare-ups) and less antibiotic usage than…

In people with cystic fibrosis (CF), treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) may reduce the risk of CF-related liver disease (CFLD) progression, according to a real-world study in France. Rates of severe liver complications were significantly lower among people with CF who were followed during the period after Kaftrio …

Women with conditions such as cystic fibrosis (CF) who planned their pregnancies after a lung transplant experienced better outcomes compared with those who did not plan their pregnancies, according to a recent study. Those positive outcomes included longer gestation periods, higher birth weights of their babies, and a lower…